Members Capital Advisors Inc. Sells 24,450 Shares of Pfizer Inc. (NYSE:PFE)

Members Capital Advisors Inc. lessened its position in Pfizer Inc. (NYSE:PFE) by 85.9% in the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 4,005 shares of the biopharmaceutical company’s stock after selling 24,450 shares during the period. Pfizer makes up about 0.3% of Members Capital Advisors Inc.’s investment portfolio, making the stock its 26th biggest holding. Members Capital Advisors Inc.’s holdings in Pfizer were worth $115,000 at the end of the most recent reporting period.

Several other large investors have also recently bought and sold shares of the company. Tokio Marine Asset Management Co. Ltd. boosted its holdings in shares of Pfizer by 4.7% in the fourth quarter. Tokio Marine Asset Management Co. Ltd. now owns 129,407 shares of the biopharmaceutical company’s stock valued at $3,726,000 after buying an additional 5,859 shares during the period. Capital Advisors Ltd. LLC boosted its holdings in Pfizer by 7.1% during the fourth quarter. Capital Advisors Ltd. LLC now owns 14,836 shares of the biopharmaceutical company’s stock worth $427,000 after purchasing an additional 978 shares during the last quarter. Cognios Beta Neutral Large Cap Fund LP boosted its holdings in Pfizer by 4.3% during the fourth quarter. Cognios Beta Neutral Large Cap Fund LP now owns 18,066 shares of the biopharmaceutical company’s stock worth $520,000 after purchasing an additional 739 shares during the last quarter. Wynn Capital LLC acquired a new position in Pfizer during the fourth quarter worth $617,000. Finally, Mizuho Securities Co. Ltd. boosted its holdings in Pfizer by 261.7% during the fourth quarter. Mizuho Securities Co. Ltd. now owns 3,700 shares of the biopharmaceutical company’s stock worth $107,000 after purchasing an additional 2,677 shares during the last quarter. Institutional investors own 68.36% of the company’s stock.

Pfizer Stock Performance

Shares of PFE traded down $0.06 during trading hours on Wednesday, hitting $26.26. The company had a trading volume of 24,501,011 shares, compared to its average volume of 41,887,898. The firm has a market cap of $148.70 billion, a price-to-earnings ratio of 72.94, a PEG ratio of 1.18 and a beta of 0.61. The business has a fifty day moving average of $27.05 and a 200-day moving average of $28.50. Pfizer Inc. has a 12 month low of $25.23 and a 12 month high of $40.37. The company has a quick ratio of 0.69, a current ratio of 0.91 and a debt-to-equity ratio of 0.69.

Pfizer (NYSE:PFE) last released its quarterly earnings results on Tuesday, January 30th. The biopharmaceutical company reported $0.10 EPS for the quarter, topping analysts’ consensus estimates of ($0.19) by $0.29. Pfizer had a net margin of 3.62% and a return on equity of 10.88%. The business had revenue of $14.25 billion for the quarter, compared to analyst estimates of $14.37 billion. During the same period last year, the firm earned $1.14 earnings per share. Pfizer’s revenue for the quarter was down 41.3% compared to the same quarter last year. Equities analysts anticipate that Pfizer Inc. will post 2.24 EPS for the current fiscal year.

Pfizer Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Friday, June 14th. Investors of record on Friday, May 10th will be given a dividend of $0.42 per share. This represents a $1.68 dividend on an annualized basis and a yield of 6.40%. Pfizer’s dividend payout ratio is 466.67%.

Analysts Set New Price Targets

Several research analysts recently commented on the stock. Guggenheim assumed coverage on shares of Pfizer in a report on Friday, February 23rd. They set a “buy” rating and a $36.00 target price for the company. Argus cut shares of Pfizer from a “buy” rating to a “hold” rating in a report on Friday, March 22nd. TD Cowen cut shares of Pfizer from an “outperform” rating to a “market perform” rating and set a $32.00 price target for the company. in a research note on Thursday, January 4th. Finally, Cantor Fitzgerald reiterated an “overweight” rating and issued a $45.00 price target on shares of Pfizer in a research note on Monday, April 15th. Eleven investment analysts have rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. Based on data from MarketBeat, Pfizer presently has an average rating of “Hold” and a consensus price target of $36.33.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.